A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

Last updated: November 17, 2025
Sponsor: Takeda
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Hives (Urticaria)

Allergy

Allergies & Asthma

Treatment

No Intervention

Clinical Study ID

NCT05469789
TAK-743-0001
MACS-2021-0616012
  • All Genders

Study Summary

The main aim of this study is to compare the HAE attacks (both total and those requiring on-demand treatment) in the 12 months before and up to 24 months after initiation of treatment with lanadelumab.

This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).

Eligibility Criteria

Inclusion

Inclusion:

  • Documented diagnosis of HAE type I or II (confirmed through laboratory testing)

  • Documented initiation of treatment with lanadelumab or due to be initiated within next 4 weeks

  • Greater than or equal to (≥)12 years of age at initiation of treatment with lanadelumab

  • ≥12 months of continuous medical record data before initiation of treatment with lanadelumab

Exclusion:

• Exposure to lanadelumab administered as an investigation product in a clinical trial setting at any point in time

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: No Intervention
Phase:
Study Start date:
June 29, 2023
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Barts Health NHS Trust

    London, England E1 1BB
    United Kingdom

    Site Not Available

  • Barts Health NHS Trust

    London 2643743, England 6269131 E1 1BB
    United Kingdom

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.